Expression and prognosis of inducible T‐cell co‐stimulator and its ligand in Chinese stage I–III lung adenocarcinoma patients

BACKGROUND: Immunotherapy has become the fastest‐adopting treatment paradigm for lung cancer with improved survival. By binding with its ligand (inducible T‐cell co‐stimulator and its ligand [ICOSL]), an inducible T‐cell co‐stimulator (ICOS) could contribute to reversing immunosuppression and improv...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhan, Xiao‐Kai, Liu, Xi‐Kun, Zhang, Sen, Chen, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Regular Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614122/
https://www.ncbi.nlm.nih.gov/pubmed/37850501
http://dx.doi.org/10.1002/ame2.12355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614122/
https://www.ncbi.nlm.nih.gov/pubmed/37850501
http://dx.doi.org/10.1002/ame2.12355

Ejemplares similares